Drugs / HMPL-A580
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07396584 | Mar 2026 → Dec 2028 expected | — | Hutchmed | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-09 | Hutchison Medipharma Limited | Results HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 hutch-med.com ↗
The preliminary results demonstrated that HMPL-A580 was stable in human, monkey, rat and mouse plasma, and showed favorable PK property in cynomolgus monkeys. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-09 | Hutchison Medipharma Limited | HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 hutch-med.com ↗ |
| 2026-03-04 | Hutchison Medipharma Limited | HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors hutch-med.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMPL-A580 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07396584 ↗ |